Bloom Science, a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis, has completed enrolment in all four cohorts of healthy adult participants as part of its Phase I clinical trial. Bloom is developing BL-001 for Dravet syndrome, a rare paediatric epilepsy that significantly impacts […]
